Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | April 24, 2017

Top 5 Hottest Cardiology Technology Topics - No. 1 FDA Slams Abbott/St. Jude

I keep close watch on our magazine’s digital analytics for both our website and social media, and it shows me in real time what readers think are the hottest topics in cardiac technology. Here is a top 5 list of some of the most note-worthy recent news items:

1. FDA Harshly Criticizes Abbott, St. Jude For Failure to Address EP Device Safety

The U.S. Food and Drug Administration (FDA) sent the most strongly worded warning letter I have seen to Abbott/St. Jude Medical (SJM) in April, blasting the company for failure to address several issues with its implantable electrophysiology (EP) devices. This included failure to take corrective action for flawed batteries in these devices, shipping recalled products to customers that were then implanted into patients, and failure to adequately protect patients with implanted EP devices from cyber-attacks. The warning letter, issued April 12, was written in response to an FDA inspection that revealed major problems with the Fortify, Unify and Assura (including Quadra) implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, and the [email protected] monitoring system used in combination with these devices. “These devices are adulterated…in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage or installation are not in conformity with the current good manufacturing practice requirements,” wrote U.S. Public Health Service Capt. Sean M. Boyd, MPH, deputy director for regulatory affairs, Office of Compliance, Center for Devices and Radiological Health, in the warning letter. “The specific violations noted in this letter and in the inspectional observations issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.”

 

2. FDA Clears First Dedicated Coronary Bifurcation Stent

The FDA granted pre-market approval (PMA) for the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions involving large side branches. It is the first dedicated bifurcation device to receive regulatory approval in the United States and addresses an unmet need in coronary interventions. About 20-30 percent of patients undergoing percutaneous coronary interventions (PCI) have a bifurcation lesion. Provisional stenting of the main branch is the current standard of care, but in many cases the side branch is not stented, leaving it vulnerable to complications like occlusion requiring bailout stenting. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

 

3. New Cardiogenic Shock Protocol Dramatically Increases Survival Rates

Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing rapid percutaneous hemodynamic support before treating the cause of a heart attack, according to a new analysis that included more than 15,000 patients across the United States. Doctors in Detroit increased survival rates from 50 to 84 percent by following the implementation of a new protocol of using a percutaneous ventricular assist device first, prior to PCI. William W. O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit, presented the data at ACC.17. He also spoke with me in a video interview. 

 

4. ACC 2017 Late-Breaking Trials

Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presented at ACC.17 in March, with links to articles specific to many of the trial presentations.

 

5. Cardiovascular Systems Initiates Voluntary Recall of Atherectomy Saline Infusion Pump

Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion Pump. CSI initiated a customer communication of the recall by letter and informed customers that they may continue to use the affected pumps until they receive a replacement. The pumps provide saline and lubricant infusion during orbital atherectomy procedures and electrical power to the orbital atherectomy device. CSI has determined that electromagnetic interference present in the hospital environment may cause the pumps to switch to standby mode during use, requiring the pump to be reset prior to continuing treatment. 

Related Content

Stroke History Higher in Asymptomatic Versus Symptomatic Atrial Fibrillation Patients
News | Stroke| June 28, 2017
Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Philips acquires purchases Spectranetics
Feature | Business| June 28, 2017
Philips Healthcare and Spectranetics Corp. announced they have entered into a definitive merger agreement for $2.05...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty System
News | Peripheral Arterial Disease (PAD)| June 26, 2017
Shockwave Medical recently announced two milestones for its Lithoplasty System for the treatment of calcified plaque in...
Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems highlighted new features of its Trinias Interventional X-ray line at the America College of
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve ar
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
Overlay Init